Compare IMCR & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMCR | PFS |
|---|---|---|
| Founded | 2008 | 1839 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.4B |
| IPO Year | 2021 | N/A |
| Metric | IMCR | PFS |
|---|---|---|
| Price | $36.21 | $20.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $67.00 | $22.50 |
| AVG Volume (30 Days) | 276.8K | ★ 913.4K |
| Earning Date | 11-06-2025 | 01-27-2026 |
| Dividend Yield | N/A | ★ 4.69% |
| EPS Growth | N/A | ★ 100.33 |
| EPS | N/A | ★ 1.96 |
| Revenue | $379,590,000.00 | ★ $836,917,000.00 |
| Revenue This Year | $32.31 | $26.36 |
| Revenue Next Year | $10.50 | $14.22 |
| P/E Ratio | ★ N/A | $10.45 |
| Revenue Growth | 28.11 | ★ 59.19 |
| 52 Week Low | $23.15 | $14.34 |
| 52 Week High | $40.72 | $21.29 |
| Indicator | IMCR | PFS |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 53.95 |
| Support Level | $35.41 | $20.57 |
| Resistance Level | $37.25 | $21.25 |
| Average True Range (ATR) | 1.58 | 0.40 |
| MACD | -0.18 | -0.08 |
| Stochastic Oscillator | 20.63 | 25.10 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.